|
KMID : 1007020060040020084
|
|
Korean Soceity of Osteroporosis
2006 Volume.4 No. 2 p.84 ~ p.90
|
|
|
The Effects of cox-2 Inhibitor on Bone Metabolism in Insulin Dependent Diabetic Rats
|
|
Lee Mi-Young
Koh Jang-Hyun
Shin Jang-Yel
Shin Young-Goo
Chung Choon-Hee
Chung Yoon-Sok
Jung Feel-Moon
Nam Soo-Min
|
|
|
Abstract
|
|
|
Objectives: To assess the effects of rofecoxib, cycloxygenase-2(cox-2) inhibitor, on bone mineral density (BMD) and bone metabolism marker in insulin dependent diabetic rat model.
Methods: Eight week-old Sprague-Dawley male rats were prepared. We administered intraperitoneal injection with streptozotocin(70mg/kg) to induce diabetes in 11 male rats and injected citrate buffer solution to 7 normal controls. One week later, a glucose level exceeding 11.1mmol/L(200mg/dL) was considered as diabetes. In diabetic rats, 6 were received rofecoxib orally in a volume of 30mg/kg/day from 9 weeks to 40 weeks. Then, they were sacrificed and measured BMD by dual-energy X-ray absorptiometry. They were also examined bone turnover markers, serum osteocalcin and urinary deoxypyridinoline.
Results: BMD values were significantly lower in diabetic controls than in normal controls. But, There was no significant difference in BMD between diabetic controls and rofecoxib treated diabetic rats. Serum osteocalcin and urinary deoxypyridinoline were not statistically significant among normal controls, diabetic controls and rofecoxib treated diabetic rats.
Conclusion: These findings suggest that BMD values are decreased in diabetes and rofecoxib has no effect on BMD in type 1 diabetes.
|
|
|
KEYWORD
|
|
|
Cyclooxygenase 2 inhibitor, diabetes mellitus, bone mineral density, osteocalcin, deoxypyridinoline
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|